Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
SOUTH SAN FRANCISCO, Calif., July 27, 2017 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its second quarter financial results on Thursday, August 3, 2017 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Thursday, August 3, 2017
- 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time
- Telephone 888-262-8942 (domestic) or 719-325-2491 (international); conference ID 5142531
- Webcast available at http://public.viavid.com/index.php?id=125162
REPLAY access
- Telephone replay will be available for 30 days beginning at approximately 7:30 p.m. Eastern Time on Thursday, August 3, 2017 by calling 844-512-2921 (domestic) or 412-317-6671 (international); conference ID 5142531
- Webcast replay will be available on the Achaogen website at www.achaogen.com in the Investors section and will be archived for 30 days following the presentation
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. FDA has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Investor Contact: Matthew Duffy 212.915.0685 [email protected] Media Contact: Denise Powell 510.703.9491 [email protected]
